Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living with Myelodysplastic Syndromes
Canada NewsWire REBLOZYL®, an erythroid maturation agent, is the first and only of its kind approved for use inCanada
Read more